Essential Thrombocythemia Latest Advances
Find the Latest Research About Essential Thrombocythemia
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8650 publications
Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program.
Journal: The Journal of clinical investigation
Published: October 29, 2026
Premature loss of a mature arteriovenous fistula after a single cannulation: Delayed diagnosis of a venous pseudoaneurysm
Journal: Nephrologie & therapeutique
Published: October 27, 2026
Retroperitoneal Hematoma in Essential Thrombocythaemia: A Diagnostic Challenge.
Journal: La Clinica terapeutica
Published: October 24, 2026
High-normal and mildly elevated bilirubin levels in prefibrotic primary myelofibrosis patients are associated with lower thrombotic risk.
Journal: Scandinavian journal of clinical and laboratory investigation
Published: October 16, 2026
Inflammatory myofibroblastic tumor of the greater omentum in a 7-year-old girl.
Journal: Archivos argentinos de pediatria
Published: October 13, 2026
Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms.
Journal: Cancers
Published: September 28, 2026
Aortic Valve Replacement Associated With Essential Thrombocythemia:Report of a Case
Journal: Kyobu geka. The Japanese journal of thoracic surgery
Published: September 10, 2026
A Novel Molecular Etiology of Paradoxical Hereditary Thrombocytosis Caused by Germline JAK2 Loss-of-Function.
Journal: American journal of hematology
Published: September 09, 2026
"Beyond the Genetic Blueprint: Disrupting the Epitranscriptomic Code in Myeloproliferative Neoplasms".
Journal: Experimental hematology
Published: September 07, 2026
Comparative study of the prognostic value of survival prognostic scoring systems in patients with essential thrombocythemia: IPSET, MIPSS-ET, AAA, and AAA
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 07, 2026
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.
Journal: International journal of clinical oncology
Published: September 06, 2026
Last Updated: 11/08/2026